TrialRetrovirology2016

Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial.

Erwann P Loret et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.